A5065902991- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Glycosylation and Glycoproteins Research
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- RNA modifications and cancer
- T-cell and Retrovirus Studies
- Renal Diseases and Glomerulopathies
- Cancer-related gene regulation
- Neutropenia and Cancer Infections
Karolinska Institutet
2016-2025
Karolinska University Hospital
2013-2022
Oslo University Hospital
2011-2019
Creative Electron (United States)
2018
Danderyds sjukhus
1985-2017
Ludwig-Maximilians-Universität München
2017
Addenbrooke's Hospital
2017
University of Minnesota
2017
Mayo Clinic in Florida
2017
Heidelberg University
2013
In 2006, we published the results of European Organisation for Research and Treatment Cancer phase III trial EORTC 20981 on role rituximab in remission induction maintenance treatment relapsed/resistant follicular lymphoma (FL). At that time, median follow-up was 33 months. Now, report long-term outcome treatment, with a 6 years.Overall, 465 patients were randomly assigned to either six cycles cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or plus CHOP (R-CHOP). Those complete...
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin entity, with median survival of about 5 years. In 2008 we reported the early - based on observation time 4 years results Nordic Lymphoma Group MCL2 study frontline intensive induction immunochemotherapy and autologous stem transplantation (ASCT), more than 60% event-free at years, no subsequent relapses reported. Here present an update after 6·5 The overall are still excellent, response duration longer 10 7·4 However, six patients have...
Summary This report represents a further update of the consensus panel criteria for assessment clinical response in patients with W aldenström macroglobulinaemia ( WM ). These have been updated light data demonstrating an improvement categorical responses new drug regimens as well acknowledgement fact that such are predictive overall outcome. A number key changes proposed but challenges do however remain and these include variability kinetics immunoglobulin M IgM ) reduction different...
MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis many studies. The impact MYC-R on may be influenced by the partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated cohort patients through Lunenburg Lymphoma Biomarker Consortium to validate prognostic significance (single-, double-, triple-hit status) DLBCL within context gene.The study included histologically confirmed morphology derived...
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy autologous stem cell transplantation. One such strategy is Nordic MCL2 regimen, developed Group. We here present 15-year updated results study after a median follow-up 11·4 years: For all patients on an intent-to-treat basis, overall progression-free survival was 12·7 8·5 years,...
Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). Polymorphisms in FcgammaRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-mediated cytotoxicity, may therefore influence responses to rituximab.Sequence analysis of the entire coding region was undertaken 58 patients with WM whose outcomes after rituximab were known.Variations five codons identified. Two commonly observed (FcgammaRIIIA-48 FcgammaRIIIA-158)...
The microenvironment influences outcome in follicular lymphoma. Our hypothesis was that several immune cell subsets are important for disease and their individual prognostic importance should be demonstrable the same analysis competition with clinical factors.Seventy lymphoma patients extreme ("poor" "good" cases) were selected a population-based cohort of 197. None 37 good-outcome died from lymphoma, whereas all 33 poor-outcome succumbed <or=5 years. Furthermore, followed long time needed...
Abstract Purpose: Follicular lymphoma is a heterogeneous disease with variable prognosis and clinical course. We hypothesized that the presence of nonmalignant T cells in microenvironment tumor may affect outcome. Experimental Design: Using flow cytometry, we evaluated T-cell subsets lymph node follicular lymphoma. All patients South Stockholm County indolent cytometry done on diagnostic between 1994 2004 were included (N = 139). Diagnosis grade (1, 2, 3a) confirmed by re-review. Flow...